Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

3.850 +0.110 (+2.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,986,673
Open 3.720
Bid (Size) 3.840 (1)
Ask (Size) 3.900 (10)
Prev. Close 3.740
Today's Range 3.700 - 3.885
52wk Range 3.580 - 8.050
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets

Performance

YTD
-32.81%
-32.81%
1 Month
-3.99%
-3.99%
3 Month
-27.50%
-27.50%
6 Month
-11.29%
-11.29%
1 Year
-41.75%
-41.75%

More News

Read More
3 Stock Gems Hiding in the Nasdaq
Via InvestorPlace
5 Of 7 AI Categories Rose, Slightly,Over Past Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: AbCellera Biologics Q4 Earnings
Via Benzinga
ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
AbCellera Reports Q1 2024 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
Via Talk Markets
AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
From AbCellera Biologics Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Via Talk Markets
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024
From AbCellera Biologics Inc.
Via Business Wire
The 7 Best Penny Stocks to Buy in Q2 2024
Via InvestorPlace
AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
From AbCellera Biologics Inc.
Via Business Wire
Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Via InvestorPlace
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.